
    
      An open-label, extension safety and tolerability study is planned for at least 12 months
      duration following the end of this study. All participants who complete the Month 12 Exit
      Visit having demonstrated adequate compliance with application of the Investigational Product
      (IP) without major Protocol Deviations (PDs) during the study will be eligible for
      participation in the extension study.

      All participants will be contacted by phone approximately 30 days following the Exit or
      Discontinuation Visit to determine if the participant has experienced any new adverse events
      (AEs)/serious AEs (SAEs) since discontinuation/completion of study treatment.
    
  